Non-Hormonal Menopause Treatment Online — Speak With a Licensed Provider

For women who cannot or prefer not to use hormone therapy, evidence-based non-hormonal treatments including paroxetine and desvenlafaxine are available — targeting vasomotor symptoms and mood disruption without estrogen.

Board-certified doctors · All 50 states · FDA-registered pharmacy · Reviewed within 24 hours

Is Non-Hormonal Menopause Treatment right for you?

Connect with a kindr-licensed provider who can evaluate whether Non-Hormonal Menopause Treatment is appropriate for your health history and symptoms.

• ✓Hot flashes and night sweats
• ✓Mood changes and anxiety
• ✓Sleep disruption
• ✓Cannot or prefer not to use estrogen
• ✓History of hormone-sensitive conditions

If you experience several of these symptoms, a kindr provider can evaluate your options and discuss whether Non-Hormonal Menopause Treatment is clinically appropriate for you.

What is non-hormonal menopause treatment?

Non-hormonal menopause treatments are prescription medications that reduce vasomotor symptoms (hot flashes, night sweats) and, in many cases, associated mood and sleep disruption — without altering estrogen or progesterone levels. The category includes select SSRIs and SNRIs (paroxetine, desvenlafaxine, escitalopram, venlafaxine), gabapentin, and the newer neurokinin-3 receptor antagonist fezolinetant.

These medications are the standard of care for women with a history of hormone-sensitive cancer, personal or strong family history of venous thromboembolism, or other conditions where estrogen is contraindicated — and for women who simply prefer a non-hormonal approach.

How non-hormonal menopause treatment works

SSRIs and SNRIs modulate serotonin and norepinephrine signaling in the hypothalamic thermoregulatory center, reducing the exaggerated heat-loss response that produces hot flashes. Gabapentin acts through calcium channel modulation and is especially useful for nighttime symptoms. Fezolinetant blocks neurokinin-3 receptors on hypothalamic KNDy neurons, directly reducing the neurologic driver of vasomotor symptoms discovered in recent decade of menopause research.

The clinical evidence

Paroxetine (7.5 mg) is the only FDA-approved non-hormonal medication specifically labeled for vasomotor symptoms of menopause, based on two randomized controlled trials showing significant reduction in hot flash frequency and severity. Fezolinetant (Veozah), FDA-approved in 2023, showed 55-65% reduction in moderate-to-severe hot flashes at 12 weeks in the SKYLIGHT trials — comparable to hormone therapy.

NAMS 2023 non-hormonal position statement identifies fezolinetant, paroxetine, desvenlafaxine, escitalopram, gabapentin, and oxybutynin as evidence-based options for vasomotor symptoms in women who cannot or choose not to use hormone therapy.

Common side effects

Most side effects are mild and settle within the first 4-8 weeks. Report anything severe or persistent to your prescriber.

• Nausea in the first 1-2 weeks of SSRIs/SNRIs
• Dizziness or fatigue with gabapentin
• Sexual side effects with some SSRIs
• Elevated liver enzymes (fezolinetant — monitored with routine labs)
• Discontinuation symptoms if stopped abruptly

Alternatives to consider

Sources

1. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
2. Depypere H et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms: the SKYLIGHT 1 and 2 trials. Menopause. 2023.
3. Simon JA et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms. Menopause. 2013;20(10):1027-1035.
4. Stuenkel CA et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.

Medically reviewed by the kindr Clinical Team. Content reflects the 2022 NAMS Position Statement and current Endocrine Society guidelines. Last reviewed 2026.

How kindr delivers care

A kindr physician reviews your health history and reasons for avoiding HRT. Non-hormonal prescription alternatives are evaluated and prescribed where clinically appropriate — shipped monthly.

What to expect

• Weeks 1-2
  Early tolerance established; initial mild symptom reduction
• Weeks 4-6
  Meaningful hot flash reduction (fezolinetant faster)
• Weeks 8-12
  Full effect established; dose refinement complete
• Months 6+
  Long-term maintenance and reassessment

Individual response varies. Your kindr provider monitors your progress and adjusts your protocol as needed at no extra charge.

Clinical standards — every time

Available to women in all 50 states

Frequently asked questions

Ready to speak with a licensed provider?

Connect with a board-certified kindr physician who can evaluate whether Non-Hormonal Menopause Treatment is right for you. No waiting rooms. No referrals. Reviewed within 24 hours.